- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01504412
Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy
March 16, 2020 updated by: Daiichi Sankyo Co., Ltd.
An Asian, Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Pregabalin-controlled, Dose-finding Study of DS-5565 in Patients With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to investigate the effectiveness and safety of DS-5565, compared to placebo, in subjects with pain associated with diabetic peripheral neuropathy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
450
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Taipei, Taiwan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 1 or Type 2 diabetes mellitus
- Painful distal symmetric polyneuropathy
- Average daily pain score is great than or equal to 4
Exclusion Criteria:
- HbA1c greater than 9.0
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DS-5565 Low Dose
DS-5565 10mg/day, administered in 2 doses.
Treatment period: 1 week titration and 6 weeks of fixed dose.
|
Oral tablets administered twice daily
|
Experimental: DS-5565 Middle Dose
DS-5565 20mg/day, administered in 2 doses.
Treatment period: 1 week titration and 6 weeks of fixed dose.
|
Oral tablets administered twice daily
|
Experimental: DS-5565 High Dose
DS-5565 30mg/day, administered in 2 doses.
Treatment period: 1 week titration and 6 weeks of fixed dose.
|
Oral tablets administered twice daily
|
Placebo Comparator: Placebo
DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
|
DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
|
Active Comparator: Pregabalin
Pregabalin capsules 300mg/day administered in 2 doses
|
Pregabalin oral capsules 150 mg administered twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy
Time Frame: Baseline to Week 7 postdose
|
The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain].
The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.
Greater mean changes (improvements) in ADPS indicated better outcomes.
A minimally meaningful effect was a mean decrease of at least 1.0 point [scale of 0 to 10] versus placebo.
|
Baseline to Week 7 postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Short Form-McGill Pain Questionnaire From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy
Time Frame: at Week 7 postdose
|
The Short Form-McGill Pain Questionnaire (SF-MPQ) Visual Analog Scale (VAS) is reported. For VAS, participants rated pain intensity on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Greater mean changes (improvements) in SF-MPQ indicated better outcomes. |
at Week 7 postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
January 3, 2012
First Submitted That Met QC Criteria
January 4, 2012
First Posted (Estimate)
January 5, 2012
Study Record Updates
Last Update Posted (Actual)
March 18, 2020
Last Update Submitted That Met QC Criteria
March 16, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
- DS5565-A-J202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on DS-5565
-
Daiichi Sankyo Co., Ltd.CMIC Co, Ltd. JapanCompletedDiabetic Peripheral Neuropathic Pain | Post-herpetic NeuralgiaJapan
-
Daiichi Sankyo Co., Ltd.Quintiles, Inc.; SRL Medisearch Inc.Completed
-
Daiichi Sankyo, Inc.CompletedPain Associated With FibromyalgiaPoland, Ukraine, Germany, Spain, United States, Austria, Portugal, Slovenia, Bulgaria, Romania, Serbia, Canada, Australia, Estonia, Russian Federation, New Zealand, Hungary, Denmark, Lithuania, Slovakia, South Africa, Latvia, Finland, Norwa... and more
-
Daiichi Sankyo Co., Ltd.Quintiles, Inc.; CMIC Co, Ltd. Japan; Quintiles Malaysia Sdn. Bhd.CompletedDiabetic Peripheral Neuropathic PainJapan
-
Daiichi Sankyo Co., Ltd.CompletedDiabetic Peripheral Neuropathic PainChina
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Daiichi Sankyo, Inc.Syneos HealthCompletedFibromyalgiaSpain, United States, Poland, Bulgaria, South Africa, Hungary, Czechia, Romania
-
Daiichi Sankyo, Inc.Syneos HealthCompletedPain Associated With FibromyalgiaUnited Kingdom, United States, Bulgaria, Romania, New Zealand, Australia, Russian Federation, Hungary, Slovakia, India, Latvia, Estonia
-
Daiichi Sankyo, Inc.Syneos HealthCompletedPain Associated With FibromyalgiaUnited States, France, Germany, Serbia, Netherlands, Denmark, Sweden, Canada, Norway, Finland, Czechia
-
Daiichi Sankyo, Inc.CompletedDiabetic Peripheral NeuropathyUnited States